Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Assets (2016 - 2026)

Collegium Pharmaceutical has reported Assets over the past 11 years, most recently at $1.7 billion for Q4 2025.

  • For Q4 2025, Assets changed 0.41% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, changed 0.41%, while the annual FY2025 figure was $1.7 billion, 0.41% changed from the prior year.
  • Assets for Q4 2025 was $1.7 billion at Collegium Pharmaceutical, up from $1.6 billion in the prior quarter.
  • Over five years, Assets peaked at $1.7 billion in Q4 2024 and troughed at $646.1 million in Q1 2021.
  • A 5-year average of $1.2 billion and a median of $1.2 billion in 2022 define the central range for Assets.
  • Biggest five-year swings in Assets: skyrocketed 92.88% in 2022 and later decreased 13.22% in 2024.
  • Year by year, Assets stood at $692.1 million in 2021, then soared by 69.65% to $1.2 billion in 2022, then dropped by 2.63% to $1.1 billion in 2023, then skyrocketed by 45.51% to $1.7 billion in 2024, then fell by 0.41% to $1.7 billion in 2025.
  • Business Quant data shows Assets for COLL at $1.7 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.6 billion in Q2 2025.